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ABSTrACT                        The completion of the first microbial genomes nearly two decades ago opened a 
completely new chapter in molecular genetics. The availability of precise sequence data permit-
ted the extended use of existing genome engineering methods, and urged the development 
of a novel set of more rapid and simple techniques for genome editing. The rapidly decreasing 
price of sequencing and DNA synthesis opened further possibilities of high-throughput genetic 
analysis and assembly. As a consequence, biomedical knowledge increased at an exponential 
rate and accelerated the development of numerous connecting fields, including that of medical 
microbiology. This review presents the reader the toolbox available today to edit and assemble 
microbial genomes and showcases the key molecular genetic strategies employed to dissect 
the mechanisms of pathogenesis and construct microbial strains for preventive or therapeutic 
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introduction
The milestones of a scientific field are rarely identified at 
their time of occurrence. This is also the case for medical 
microbiology, a discipline which through its spectacular 
progress, has made one of the most important contributions 
to improving the expectancy and quality of human life. The 
prevention, diagnostics and therapy of microbial infections 
available today would be unimaginable without the knowl-
edge cumulated in this field. Leuwenhoek’s first description 
of microbial cells (bacteria, fungi and protozoa) in a raindrop 
using a microscope opened the way to studying microbial 
morphology, but the relation of bacteria to human diseases 
was to come nearly two centuries later. Pasteur’s experimen-
tal evidence for biogenesis, and disapproval of spontaneous 
generation was an important support for the germ theories 
of fermentation and disease. Koch’s postulates founded the 
golden age of discovering the causative agents of numerous 
infectious diseases. The discovery of penicillin by Fleming 
opened a whole new era of antibacterial treatment. In the sec-
ond half of the twentieth century, the application of molecular 
genetic analysis in bacteria and bacteriophages granted a 
continuous progress within medical microbiology, paving 
the way for the exponential explosion of information and 
possibilities brought about by the first completed microbial 
genome sequences in 1997. 
Despite being a recent event, the onset of whole-genome 
sequencing is generally considered to be a milestone within 
life sciences. The consequential acceleration in the growth 
of genomic sequence data introduced a revolution in at least 
three scientific subdivisions: i) evolutionary biology, where 
sequence data warranted the construction of phylogenetic 
trees of previously unseen detail; ii) systems biology, where 
the building of genome-scale models finally became a reality; 
and iii) molecular genetics, where the exact and complete 
DNA sequences permitted the targeted modification of any 
gene of choice to unravel its function. This review focuses 
on a subset of the third category, illuminating the results and 
possibilities of engineering microbial genomes with the aim 
of promoting human health. Prominent examples will be 
given of projects where bacteria or phages harboring precisely 
edited genomes are used to prevent or treat diseases, or at least 
have been shown to work in proof of principle experiments. 
To give the reader a complete picture, the most commonly 
used targeted genome editing and genome assembly tech-
niques will be introduced first, with special attention to their 
application in a multiplex or high-throughput manner.
Genome editing
The prerequisite of any project involving genome engineer-
ing, irrespective of its scale, was the development of meth-
ods capable of introducing precise and planned changes in 
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the genome of a bacterial cell. Therefore, before providing 
examples of strains engineered for biomedical studies or ap-
plications, we must give a brief introduction on the techniques 
available for such purposes. 
Suicide plasmids
The earliest and most classical approach relies on condi-
tionally replicative plasmids (Ruvkun and Ausubel 1981). 
These plasmids, also referred to as suicide plasmids, cannot 
replicate if the conditions change from permissive to non-
permissive. In practice, this can mean a change in temperature 
(Hamilton et al. 1989), a change in the propagating host cell 
(Gutterson and Koshland 1983), or the loss of a protein factor 
required for replication (Miller and Mekalanos 1988). These 
plasmids, like most others, carry a selection marker (usually 
an antibiotic resistance gene). Non-permissive conditions 
cause the loss of the plasmid from the majority of the cells, 
leading to their death, or cessation of growth during antibi-
otic selection. A small subpopulation can survive, however, 
due to the integration of the plasmid into the genome. The 
process of integration is usually homologous recombination, 
mediated by the RecA recombinase of the cell. The locus of 
integration can be controlled by cloning a certain genomic 
segment into the plasmid, thereby providing a substrate for 
the homologous recombination (Fig. 1). The cloned genomic 
fragment is usually a mutated variant of the genomic allele, 
carrying an insertion, deletion or sequence alteration within 
its central part. In the simplest case, the integration itself 
can provide the experimenter a sufficient genomic modifica-
tion, since it can mean the stable genomic propagation of a 
mutated gene, and all other genes originally present on the 
plasmid. However, this scenario results in the duplication of 
the targeted genomic segment, as well as the retaining of the 
antibiotic resistance gene within the genome, both of which 
can limit downstream experiments. Therefore, the excision 
Figure 1. Suicide-plasmid mediated genome editing. Blue boxes represent regions of homology. abr: antibiotic resistance.
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of the integrated plasmid is usually necessary. This process, 
referred to as the resolution of the cointegrant is an intramo-
lecular homologous recombination, taking place between the 
duplicated segments (Fig. 1). The result can be either the wild 
type allele or the mutated allele remaining in the genome, 
depending respectively on whether the second recombination 
takes place in the same end or opposite end of the integrated 
genomic segment, relative to the site of integration (Fig. 1). 
The alternative outcomes of the resolution can be discrimi-
nated by colony-PCR, phenotypic tests, genome hybridization 
or sequencing. The resolution process itself is a rare event, but 
it can be selected for if a counterselective marker (e.g., sacB) 
is present on the integrated plasmid (Blomfield et al. 1991). 
Better yet, resolution can be both mediated and selected for 
by either one of two elegant techniques: i) re-activating the 
origin of replication of the plasmid (Biswas et al. 1993), or ii) 
cleaving the cointegrant in vivo with a homing endonuclease, 
and thereby facilitating the second recombination step by 
providing free DNA ends (Pósfai et al. 1999). Importantly, 
suicide plasmid-mediated genome editing can be used to 
generate scarless genomic modifications, meaning that no ex-
ogenous sequence is left behind on the chromosome, besides 
the planned changes. Its drawback of requiring the cloning of 
relatively long (several hundreds of bps) stretches of DNA is 
counterweighted by the fact that it is freely available in the 
public domain.
Suicide plasmids have been used in complex schemes 
(e.g., facilitating genome sequencing; Wild et al. 1996), 
but are mostly used to create simple knockout strains of 
pathogens. This is usually done with the aim of verifying the 
function of putative virulence genes, but hypovirulent strains 
applicable as vaccines can also be engineered this way. For 
example, the 13 kbp-long multi-drug resistance locus of Sal-
monella enterica serovar Typhimurium was deleted using a 
temperature sensitive suicide plasmid (Sahu et al. 2013). The 
deletion strain displayed decreased colonization and prolifera-
tion capabilities in Caenorhabditis elegans, as well as an al-
tered immune response of the infected host. In another work, 
the genes encoding the lethal toxin and the edema toxin of 
Bacillus anthracis were deleted separately and in combination 
to study their roles in disrupting a human brain microvascular 
endothelial cell monolayer, or during the in vivo infection of 
mice (Ebrahimi et al. 2011). Interestingly, the two individual 
deletion mutants performed in an opposite fashion in the two 
virulence tests. A further project applying suicide plasmids 
to study virulence factors was the work of Horzempa et al. 
(2010), who deleted the pyrF gene of Francisella tularensis 
to obtain pyrimidine auxotrophic cells. These lost their ability 
to replicate in primary human macrophages, but surprisingly 
retained virulence during infection of chicken embryos and 
in the murine model of pneumonic tularemia. An example of 
vaccine development using suicide plasmids was published 
by Lee and co-workers (2007). In that work, the intranasal 
vaccination of mice with the rpoS, phoP double mutants of 
Salmonella enterica serovar Typhi was shown to provide ef-
fective immunity against the wild type strain.
Recombineering
The second widely used strategy, nowadays referred to as 
“recombineering” integrates linear DNA into the chromo-
some via a double homologous recombination process (Fig. 2) 
(Murphy 1998). Recombineering displays several important 
advantages over suicide plasmid-based methods: it does not 
require cloning, and the terminal homolog regions of the DNA 
fragment are short enough to be accommodated on primers. 
In several fungal and bacterial species, e.g., Saccharomyces 
cerevisiae (Baudin et al. 1993), Bacillus subtilis (Fabret et 
al. 2002) or Sulfolobus acidocaldarius (Grogan and Stengel 
2008) the effectiveness of the housekeeping recombinase 
machinery allows the process to efficiently take place in 
wild type cells. In Escherichia coli, however, the expression 
of phage recombinases is usually necessary, either by acti-
vating the RecET operon of the endogenous Rac prophage 
(Kusano et al. 1994) or by transforming the Redαβγ genes 
of phage lambda (Murphy 1998). Analogously, expression 
of recombination-protein gp61 of mycobacteriophage Che9c 
(van Kessel and Hatfull 2007) has been exploited for genome 
editing in Mycobacteria. Phage-derived recombinase pro-
teins, comprising an endonuclease and/or an ssDNA-binding 
protein have also been identified in Vibrio cholerae (Chen et 
al. 2011) and Clostridium perfringens (Dong et al. 2014), 
opening the possibility of applying recombineering for these 
species as well.
The classical scheme of recombineering applies double 
stranded linear DNA in a two step procedure, similarly to that 
of suicide plasmids. During the first step, an antibiotic is used 
to select for cells carrying the cointegrate. This step alone is 
sufficient to disrupt or completely delete a chromosomal gene 
(referred to as “knock-out”), or to integrate a gene (known 
as “transgene knock-in”). In most cases, however, unwanted 
exogenous sequences are removed in a second step, using 
either one of three methods. As a first alternative, site specific 
recombinases, e.g., FLP, Cre or Vika can be used to facilitate 
recombination between two short target sites (FRT, loxP or 
vox, respectively) (Broach and Hicks 1980; Sternberg and 
Hamilton 1981), thereby removing all sequences in-between 
(Fig. 2A). This method is simple and efficient, but a recombi-
nase target site is retained in the genome, which can interfere 
with downstream experiments. The second alternative is to 
apply a second round of recombineering using a DNA frag-
ment that consists solely of the scarless joint (Fig. 2B). This 
usually requires inclusion of a counterselective marker on the 
initially inserted segment. The third technique for removing 
the unwanted section of the insert is to use three homology 
boxes, as shown on Figure 2C. The two terminal boxes war-
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rant integration into the genome, while a third, internal box 
homologous to a nearby genomic segment allows a second 
round of recombination, eliminating all sequences between 
this box and the nearby segment. The efficiency of this tech-
nique can be greatly enhanced by in vivo cleavage of the insert 
with a homing endonuclease (Jurica and Stoddard 1999) 
which provides free DNA ends for recombination and selec-
tion against insert-bearing cells. The two latter techniques are 
suitable for scarless genome engineering, since they leave no 
unwanted sequences behind.
Lately, an alternative scheme of recombineering is gain-
ing ground, especially in high-throughput genome engineer-
ing. This method uses single stranded DNA, and only a 
single step procedure for genome editing (Ellis et al. 2001). 
Briefly, 40-80 bp long oligonucleotides corresponding to the 
lagging strand of DNA replication are electroporated into 
cells expressing the lambda Redβ recombinase protein. The 
efficiency of their recombination into the genome is further 
enhanced by eliminating the methyl-directed mismatch repair 
system of the host (Costantino and Court 2003), by using 
chemically modified nucleotides (Wang et al. 2011), or by 
overloading or eliminating host endonucleases (Sawitzke et 
al. 2011). Mutations can be introduced into the genome this 
way with frequencies between 0.1 and 50%, allowing simple 
screening by colony-PCR to find recombinants.
As demonstrated for suicide plasmids, recombineering is 
also primarily used to generate null-mutants, thereby aiding 
the identification of the function of the deleted gene. In a 
study describing a novel inhibitor of pyocianin production and 
biofilm formation of Pseudomonas aeruginosa, the putative 
target of the inhibitor was validated using null mutants of 
quorum-sensing receptors (O’Loughlin et al. 2013). Recom-
bineering in M. tuberculosis applying the mycobacteriophage 
gp61 revealed that an asparagine transporter is necessary for 
this pathogen to assimilate nitrogen, as well as to deal with 
acid stress within the phagosome (Gouzy et al. 2014). Mutants 
lacking this transporter displayed attenuated growth in murine 
macrophages and infected adult mice. Removal of virulence 
factors to generate attenuated live vaccine strains was also 
demonstrated with λ-Red recombineering: deletion of the 
virG gene of Shigella flexneri led to a decreased invasion of 
epithelial cell monolayers as well as a lack of inflammation 
Figure 2. Recombineering. Three alternative strategies to engineer markerless genomic deletions are shown. Blue and pink boxes represent 
regions of homology, red boxes depict targets of a site-specific recombinase. abr: antibiotic resistance; csm: counterselective marker; HDR: 
homology-directed recombination.
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upon challenging the conjunctiva of guinea pigs (Ranallo et 
al. 2006). Recombineering is also capable of editing episomal 
DNA, including high-copy plasmids (Thomason et al. 2007), 
bacterial artificial chromosomes (Muyrers et al. 1999), and 
bacteriophages. Phage genome editing, earlier done exclu-
sively in the lysogenic state (Oppenheim et al. 2004) has 
lately been demonstrated to be possible in the lytic state as 
well, both with λ-Red (Fehér et al. 2012a) and with Che9c 
gp61 recombinase proteins (Marinelli et al. 2008). The use 
of engineered phages in curing model diseases is a promising 
field of synthetic biology (see below).
Group II introns
Less frequently used, but important tools of targeted genome-
editing are the group II introns, also called targetrons (Lam-
bowitz and Zimmerly 2004). The natural forms of these ele-
ments can increase their copy numbers in the genome of their 
host by a mechanism called retrohoming. During this process, 
the RNA transcribed from these elements goes through 
maturation, and forms a lariat structure (Fig. 3). This lariat 
can attack and insert into double-stranded DNA (dsDNA) by 
“reverse splicing”, forming a single-stranded RNA insertion. 
This intermediate form is reverse transcribed, and subse-
quently repaired to form a dsDNA insert by the endogenous 
DNA repair mechanisms of the host cell. The RNA matura-
tion, DNA cleavage and reverse transcription are all catalyzed 
by a single enzyme called the intron encoded protein (IEP). 
Using a computational tool (Perutka et al. 2004), the insertion 
process can be specifically retargeted by modifying the seg-
ments of the intron responsible for target binding. The biggest 
advantage of targetrons is their applicability in cells that are 
recalcitrant to homologous recombination, thereby providing 
the user an unusually broad host range genome–engineering 
tool (Rodriguez et al. 2009).
The most straightforward application of group II introns 
is to interrupt genes, similarly to their natural mode of ac-
tion. They can be used to introduce cleavage sites into the 
chromosome, thereby allowing the generation of DSBs fol-
lowed by their correction by homologous recombination of 
a co-transformed linear DNA fragment. Targetrons are also 
capable of inserting cargo genes (Frazier et al. 2003), or tar-
get sites of site-specific recombinases into the genome. With 
properly integrated recombinase target sites, one can engineer 
deletions, inversions or cut-and-paste translocations of chro-
mosomal segments upon the cellular expression of the cor-
responding recombinase (Enyeart et al. 2013). The insertion 
frequency of the Lactococcus lactis Ll.LtrB group II intron 
is in the range of 1% in E. coli, (Lambowitz and Zimmerly 
2004) meaning that PCR-based screening can be sufficient to 
find cointegrants even if using systems that lack a selection 
marker. If certain experimental setups or hosts require elevat-
ing the rate of insertion, one can apply selection when includ-
ing a retrotransposition-activated selectable marker (RAM) 
in the intron. The first RAM was a Trimethoprim resistance 
gene, interrupted by a group I intron that goes through splic-
ing during the retrotransposition process, thereby allowing 
the selection of co-integrants with nearly 100% specificity 
(Zhong et al. 2003). 
Targetrons have been applied to engineer the genes of 
numerous gram-positive and gram-negative bacteria. To men-
tion medically relevant examples, two putative replication 
origins of plasmid pXO1 from Bacillus anthracis have been 
disrupted one-by-one to validate their independent functional-
ity, and measure the resulting plasmid copy numbers (Akhtar 
and Khan 2012). In another instance, the mtlA gene of Vibrio 
cholerae was knocked out, verifying its function in mannitol 
and sorbitol uptake (Kumar et al. 2010). A two-component 
regulator of Yersinia pseudotuberculosis, responsible for cold-
tolerance was also inactivated using this technique (Palonen 
et al. 2011). Besides engineering knock-out strains for gene 
functionality studies, group II introns have also been used to 
construct transgenic bacterial strains for the purpose of vac-
cination. For example, recombinant Clostridium perfringens 
Figure 3. Retrohoming of a group II intron (Enyeart et al. 2013).
RT: reverse transcriptase; RNP: ribonucleoprotein
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cells are potentially useful vehicles for oral delivery of anti-
gens to the gut-associated lymphatic tissue (GALT). However, 
plasmid-borne expression of the antigen necessitates the use 
of resistance markers for plasmid maintenance, which would 
raise the risk of iatrogenic transmission of antibiotic resis-
tance. Another hazard connected to clostridia is their potential 
to produce various toxins. To solve these two problems in one 
step, Chen et al. (2007) used a targetron to knock-in the p27 
gene of the Simian Immunodefiency Virus into the theta toxin 
gene (pfoA) of the C. perfringens genome, thereby creating a 
safer strain for vaccination against the viral antigen. Another 
example of engineering an attenuated vaccine strain was the 
deletion of the 15 kbp-long pathogenicity island 1 of Staphy-
lococcus aureus using two flanking targetrons and the Cre/lox 
site specific-recombinases (Enyeart et al. 2013).
The CRISPR/Cas system
Recently, a novel technique relying on the bacterial CRISPR/
Cas system opened an entirely new chapter in genome edit-
Figure 4. (A) Structure and function of a CRISPR array. (B) Utility of the Cas9 protein as an RNA-guided nuclease. The specificity of the cleavage 
is warranted by the base-pairing of the sgRNA and the target DNA. PAM: protospacer adjacent motif; NHEJ: non-homologous end joining; 
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ing, and most probably in general molecular genetics as well. 
The activity of CRISPR/Cas, in its wild type form is often 
referred to as the adaptive immune response of bacterial cells 
(Horvath and Barrangou 2010; Jinek et al. 2012). Its presence 
has been demonstrated in 45% of bacterial and 83% of archeal 
genomes (Sampson and Weiss 2014). The name CRISPR, 
which stands for clustered regularly interspaced palindromic 
repeats, originates from its genetic organization, shown on 
Fig. 4A. Key elements of the CRISPR loci are the direct 
repeats which alternate with variable spacers, remnants of 
captured exogenous plasmid and phage sequences. The spac-
ers are responsible for specific recognition of their maternal 
DNA sequences upon their re-entry into the cell. The long 
primary transcript of the CRISPR locus (the pre-crRNA) is 
processed into short mature CRISPR RNAs (crRNAs) that 
consist of a single repeat and a spacer, with the latter target-
ing potential invader sequences. Importantly, the targeting 
process is a Watson and Crick base pairing, which leads to 
the cleavage of the target DNA by the Cas enzymes. 
The Cas proteins make up a heterogeneous family har-
boring domains reminiscent of endonucleases, helicases, 
polymerases, and polynucleotide-binding proteins. Cas genes 
usually lie in the proximity of the repeat-structure, but are 
transcribed separately from the pre-crRNA. To date, three 
classes of Cas have been described, that are distinct in their 
molecular mechanisms. Type I and III utilize a complex of 
Cas proteins (called CASCADE) both for RNA maturation 
and for target DNA cleavage. In the case of the type II system, 
a single enzyme, Cas9 is sufficient to disrupt the target, which 
explains why most applications use this system for gene edit-
ing. It is important to note, that for type II CRISPR/Cas, the 
trans-activator CRISPR RNA (tracrRNA), complementary 
to the repeat of the CRISPR array, is required both for RNA 
maturation and the activation of Cas9. In practical applica-
tions using Cas9 as an RNA-guided endonuclease, the natu-
ral setup is further simplified by using a single guide RNA 
molecule (sgRNA) that unites the roles of the crRNA and the 
tracrRNA in target recognition and Cas9 activation, respec-
tively (Fig. 4B). Importantly, for type I and II CRISPR/Cas, 
the targeted sequences must include a protospacer adjacent 
motif (PAM), which slightly limits the freedom of guiding the 
cleavage process. Today, several websites are available that 
aid the design of sgRNAs (http://www.e-crisp.org/E-CRISP/
designcrispr.html; http://zifit.partners.org/ZiFiT/) (Sander et 
al. 2010; Heigwer et al. 2014).
The rapid expansion of CRISPR/Cas-based genome engi-
neering projects derives from its three major merits. The first 
is its adaptability to multiple domains of life. For example, the 
type II system of Streptococcus pyogenes has been applied in 
species as diverse as E. coli (Jiang et al. 2013), yeast (DiCarlo 
et al. 2013), C. elegans (Friedland et al. 2013), Drosophila 
(Gratz et al. 2013), Danio rerio (Hwang et al. 2013), rice 
(Feng et al. 2013) and human cell lines (Cho et al. 2013). 
The second advantage is the simplicity of design. Earlier 
programmable nucleases like zinc finger nucleases, transcrip-
tion activator-like effector nucleases (TALENS) or engineered 
meganucleases required protein design, which significantly 
increased the time, effort and financial requirements of the 
engineering project (for a review of these systems, see (Sun 
et al. 2012)). Since the CRISPR/Cas system relies solely on 
base-pairing of the guide RNA with the target, the design 
process is incomparably simpler. The third merit is the flex-
ibility of the system, which gave way to multiple derivative 
techniques, discussed below. 
The basic application of CRISPR/Cas is introducing a 
double-stranded break (DSB) into the target DNA. In eu-
karyotes, this is usually sufficient to inactivate the gene, since 
non-homologous end joining, the primary system repairing 
DSBs often leads to a frameshift mutation (Sun et al. 2012). 
For more precise and predictable genome engineering, a small 
linear DNA fragment, referred to as the editing template is 
provided along the cleavage process, which bridges the free 
DNA ends using homology-directed repair. With proper 
design of the editing template, one can engineer arbitrary 
genetic alterations, including gene knock-outs and knock-
ins. Mutants of the Cas9 protein that nick the target DNA 
instead of cleaving it, have been applied to increase target 
specificity: by introducing nicks to opposite DNA strands 
at two adjacent sites, one can effectively double the length 
of the target identified during complete cleavage (Ran et al. 
2013). This strategy can increase specificity, similarly to the 
classic trick of extending restriction endonuclease target sites 
(Pósfai and Szybalski 1988). Cas proteins that completely 
lack endonuclease activity, called dead Cas9 (dCas9) have 
been applied to alter gene expression by either one of two 
mechanisms: they can either inhibit transcription initiation via 
promoter-binding, or can be fused to a transcription activator 
or repressor and promote expression up- or down-regulation, 
respectively. Another application of the specific targeting 
function is using dCas-GFP fusions for fluorescent visualiza-
tion of certain genomic segments in vivo. 
The amazing popularity that CRISPR/Cas has gathered 
in the past two years is mostly attributable to its applicability 
in mammalian cells. Not surprisingly, due to the alternative 
possibilities available in prokaryotes, the number of publica-
tions reporting its application grows at a much slower rate. 
The possibilities are nevertheless given, as exemplified by the 
following proof-of-concept studies. For example, the type II 
CRISPR/Cas of various Streptococcus species has been suc-
cessfully applied to edit the genomes of S. pneumoniae, E. 
coli, Lactobacillus reuteri and Streptomyces coelicolor (Jiang 
et al. 2013; Oh and van Pijkeren 2014; Huang et al. 2015). 
The DSB introduced by Cas has been shown to both facili-
tate the recombination of the editing template, and provide a 
selection against the wild-type genotype (Jiang et al. 2013). 
In E. coli and L. reuteri, the function of the editing templates 
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can be fulfilled by oligonucleotides if the recombination is 
mediated by phage recombinases, thereby combining recom-
bineering with the CRISPR/Cas system. If no bridging DNA 
is provided, the DSB causes cell death in most bacteria, and 
has been demonstrated to be applicable in removing bacterial 
strains from a mixed population based on sequence content 
(Gomaa et al. 2014). This strategy can be used to generate 
“smart antibiotics”, targeting only those bacteria that present 
a danger to the host (see below). For gene expression down-
regulation, also called CRISPR-interference (CRISPRi), 
both type I and type II CRISPR/Cas has been applied in E. 
coli (Bikard et al. 2013; Luo et al. 2015). The engineering of 
bacteriophages has also been demonstrated with these two 
types of CRISPR/Cas (Kiro et al. 2014; Martel and Moineau 
2014). Perhaps the largest therapeutic promise of CRISPR/
Cas systems lies in the in vivo inactivation of proviral DNA 
inside eukaryotic cells (see below).
Large scale engineering of microbial genomes
As soon as techniques for markerless genome editing were 
available, the door was open for repeated engineering of bac-
terial or fungal chromosomes. Projects that have introduced 
multiple targeted changes into genomes are numerous. We 
will concentrate only on two special cases: genome reduction, 
and multiplex parallel (automated) genome engineering. 
Genome reduction
The first publication that reported the reduction of a microbial 
genome was the work of Kolisnychenko et al. (2002), who ap-
plied recombineering to remove the 12 largest strain-specific 
islands of E. coli K-12. Since then, genome reduction has 
been applied in at least six bacterial (E. coli, Bacillus subti-
lis, Corynebacterium glutamicum, Legionella pneumophila, 
Pseudomonas putida, Streptomyces avermitilis) and three fun-
gal (Saccharomyces cerevisiae, Schizosaccharomyces pombe, 
Aspergillus oryzae) species (for a recent review, see Fehér 
2014). The motivation behind most projects is usually one of 
the two following factors: i) to answer fundamental questions, 
e.g., seeking the minimal gene set required for life, investi-
gating the evolutionary role of mobile elements (Fehér et al. 
2012b) or ii) optimization of the strain for biotechnological 
applications, e.g., gene cloning or protein overproduction. In 
the latter case, unwanted cellular components are removed 
with the aim of increasing cellular predictability and stability, 
or redirecting energy and metabolite resources towards the 
production of useful compounds (Umenhoffer et al. 2010). An 
example that applies genome reduction for improved produc-
tion of pharmaceuticals is the work of Komatsu and co-work-
ers (2010). In their work, they deleted the 1.5 Mbp-long left 
subtelomeric region of the linear S. avermitilis chromosome. 
This eliminated the production of the endogenous secondary 
metabolites avermectin and filipin, and two further deletions 
removed the entire gene set of oligomycin biosynthesis. As a 
result, the reduced-genome strain, when transformed with the 
appropriate genetic constructs displayed increased production 
yields of certain pharmaceuticals, including aminoglycosides, 
polyketides, non-ribosomal peptides and terpenes. In fact, 
the engineered strain produced streptomycin and cephamy-
cin with higher yields than the Streptomyces strains that the 
heterologous pathways originated from. 
Figure 5. Multiplex Automated Genome Engineering. Boxes of different color represent oligonucleotides targeting different genomic loci, or 
oligonucleotides targeting the same locus but carrying different mutations.
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Highly parallel genome engineering
In 2009, the group of George Church introduced the quanti-
tative upscaling of the recombineering process (Wang et al. 
2009). Multiplex Automated Genome Engineering (MAGE) 
employs the λ-Red recombinase and a pool of oligonucle-
otides to target multiple genomic loci, simultaneously (Fig. 
5). No direct selection is applied for individual recombination 
events; one can however employ a general selection pressure 
to direct the phenotype in the direction of choice. The oli-
gonucleotides can be designed to introduce defined changes 
(insertions, deletions or base exchanges), but can also carry 
degenerate segments to allow randomization of the targeted 
region. This way the experimenter can implement directed 
evolution where the increased mutation rate is limited to a 
few loci of interest. The application of MAGE in repeated 
cycles allows generating a tremendous combinatorial library 
of mutants and the exploitation of genetic interactions where 
the contributions from multiple neutral mutations result in a 
fitness increase. 
In a proof of principle experiment, MAGE was used to 
target 24 genes related to lycopene production on the E. coli 
genome. Apart from deleting some draining pathways, most 
of the oligos were designed to introduce changes in the ribo-
some-binding sites of genes involved in production, thereby 
altering their translation rate. This generated a combinatorial 
library of mutants, where the balanced overexpression of 
enzymes, resulting in maximal lycopene production, was se-
lected relying on the color of the colonies (Wang et al. 2009). 
In a later work, the power of MAGE was combined with the 
specificity of transcription factors sensitive to the target com-
pound. This allowed linking target production to cell fitness 
and automatic selection of the best producer strains from a 
vast library of mutants, thereby increasing naringenin and 
glucaric acid production rates 36- and 22-fold, respectively 
(Raman et al. 2014). One potential disadvantage of MAGE is 
the requirement of a mismatch-repair defective (mutS-) host 
cell to potentiate the recombination process, which uninten-
tionally increases the overall mutation rate of the genome 
100 fold. Recently, the rate of such off-target mutations has 
been decreased by applying a system that inactivates mutS 
only temporarily, thereby warranting the stable maintenance 
of engineered strains (Nyerges et al. 2014). 
Genome synthesis
Genome synthesis is the de novo assembly of DNA molecules 
corresponding to the genome of existing or planned micro-
organisms. The basic building blocks of this process are the 
oligonucleotides, chemically synthesized ssDNA molecules 
usually falling into the size range of 30 to 150 bases. The 
toolbox available for genome synthesis is quite vast, due to 
the fact that stitching together pieces of DNA has been car-
ried out for decades within the bounds of genetic cloning. 
Although some of these methods are very elegant and would 
deserve a detailed description, discussing each of them would 
exceed the limits of this publication. We therefore concentrate 
only on the ones that have already been applied in genome 
synthesis, and direct the reader to earlier reviews to obtain 
a complete picture on all the possibilities of DNA assembly 
(Ellis et al. 2011; Cobb et al. 2013).
Assembling oligonucleotides to longer stretches of ds-
DNA, referred to as gene synthesis is frequently outsourced 
to commercial providers today. There are two basic in vitro 
methods to carry out this task. The first one relies on overlap-
ping phosphorylated oligonucleotides that completely span 
both strands of the target DNA. These are stitched together 
in the course of ligase chain reaction (LCR), a cyclic process 
of annealing and ligation (Grundstrom et al. 1985). The sec-
ond method uses partially overlapping oligonucleotides that 
only partially cover the two strands. The gaps in between 
two neighboring oligos are filled up by Taq polymerase in 
overlap-extension reactions, using the complementary strand 
as a template. After numerous cycles of this reaction, called 
Polymerase Cycling Assembly, a significant portion of the 
products will be the nick-free full length target DNA molecule 
(Stemmer et al. 1995). The first method is more expensive, the 
second one is more error-prone, and both require sequence-
verification of the final product. A combination of these two 
strategies has been successfully applied to assemble the 5.4 
kbp genome of the PhiX174 phage from 42 bp oligonucle-
otides in a time frame of two weeks (Smith et al. 2003). 
Several methods have been used to assemble gene-sized 
fragments into genomes. The first and most fundamental 
one is restriction-ligation. Despite its numerous drawbacks 
(slowness, size limitation of fragments, limited re-use of sites, 
sequence scars remaining at the joints), it was applied in the 
first assembly of a synthetic polyovirus (Cello et al. 2002). 
Although several in vitro methods have been developed to 
circumvent these disadvantages, only one of them has been 
applied to date in genome synthesis. This method, nowadays 
referred to as Gibson assembly, is an in vitro recombination 
of overlapping dsDNA fragments. In the most popular version 
of the Gibson technique, the T5 exonuclease is used to chew-
back the 5’ ends of the dsDNA molecules. The emerging 3’ 
overhangs are extended by the Taq polymerase after annealing 
and are ligated by the Taq ligase, all in an isothermal reaction 
at 50 °C (Gibson et al. 2009). This method has been used 
to assemble the 16.3 kbp-long circular genome of murine 
mitochondria in multiple hierarchical rounds, starting from 
600 overlapping oligonucleotides (Gibson et al. 2010a). It 
has also been demonstrated to be capable of assembling the 
590 kbp Mycoplasma genitalium genome from four pieces 
(Gibson et al. 2009).  
Another major strategy to assemble genome-sized DNA 
is to use the remarkable, in vivo recombination capacity of 
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S. cerevisiae. This method, called transformation associated 
recombination (TAR) cloning only requires having 60 bp 
overlaps among the transformed dsDNA segments and in-
cluding a yeast replication origin to allow forming a circular 
yeast plasmid that comprises the entire synthetic genome 
(Fig. 6) (Gibson et al. 2008b). The power of the method has 
been demonstrated in the assembly of the 590 kbp-long M. 
genitalium genome from 25 pieces (Gibson et al. 2008a), or 
the construction of the 1.08 Mbp-long M. mycoides genome 
in multiple hierarchical rounds, starting from synthetic DNA 
fragments of 1 kbp (Gibson et al. 2010b).
If a bacterial genome is assembled in vitro, or inside a 
eukaryotic cell (as in the examples above), a special technique 
is required to insert it into a bacterial cell to be “booted”. This 
special form of transformation, called whole genome trans-
plantation (Lartigue et al. 2007) was used to insert a synthetic 
M. mycoides genome into M. capricolicum cells and obtain M. 
mycoides offspring controlled by the synthetic genome. The 
obtained cells were defined as synthetic, and are hallmarks 
of bottom-up engineering of bacterial genomes. However, 
genome-scale cellular models do not currently permit the 
assembly of genomes with a gene content significantly dif-
fering from those of wild type cells. For trial-and-error type 
of genome engineering, editing existing genomes is incom-
parably simpler and less expensive. The major value of the 
developed methodologies (TAR cloning and whole genome 
transplantation) seems to be the ability to clone the genomes 
of species for which no genome engineering techniques are 
available. These genomes could be edited in yeast, and then 
re-transplanted into wild-type cells to obtain engineered 
offspring (Fig. 7) (Lartigue et al. 2009).
Although the power of genome assembly is readily ap-
parent, its affordability is yet to be seen. Currently, only 
one project has been published that assembled a microbial 
genome for biomedical purposes. The workgroup that syn-
thesized the 7.5 kbp-long polyovirus genome discovered that 
introducing novel restriction sites in coding regions as silent 
mutations, necessary for the assembly had a severe deleteri-
ous effect on the in vivo neurovirulence of the virus (Cello 
et al. 2002). To turn this side effect into a benefit, the group 
re-synthesized the poliovirus genome, this time intention-
ally using rare codon-pairs throughout the capsid-encoding 
region. The result was a strain with perfect immunogenicity 
but 10 000-fold reduced efficacy in murine neurovirulence 
assays due to a decreased rate of translation. The synthetic 
virus elicited a protective immune response against wild-type 
poliovirus in a mouse model. Such viral strains could be ideal 
vaccine candidates, since their regaining of virulence would 
require a high number of reverse mutations and therefore has 
a negligible chance (Coleman et al. 2008).
Promoting health via microbial genome 
engineering
This section will showcase notorious examples of using engi-
neered bacteria and bacteriophages for treating or preventing 
various diseases. Metabolic engineering projects, i.e. those 
involving the microbial production of drug precursors, neutra-
ceuticals or other fine chemicals intended for medical use will 
not be discussed, for these represent a separate and concise 
field on their own (for a review, see Woolston et al. 2013). Nor 
will we discuss the use of wild type bacteria or bacteriophages 
as probiotics or as phage-therapy tools, respectively. We must 
note however, that the experience accumulated by the two 
latter disciplines provided a strong support for many of the 
following applications that use the genetically-engineered 
derivatives of the wild type agents.
Engineering live, attenuated bacterial strains by knocking 
out virulence genes for vaccination purposes is a long-proven 
strategy. An even more resourceful approach is to alter, or 
broaden the immunogenicity of a strain, thereby eliciting an 
immune response that is protective against further species. 
The first example of the latter dates back to 1993, when Con-
nell and co-workers expressed the gp63 surface proteinase 
of Leishmania in the cytosol of Mycobacterium bovis BCG 
cells (Connell et al. 1993). Mycobacterial cells were chosen 
as the vaccine delivery vehicle for they had been proven to 
Figure 6. Transformation Associated Cloning in yeast (Gibson et al. 
2008b). Thin lines represent the DNA to be assembled and cloned. Blue 
and orange boxes represent bacterial and yeast replication origins, 
respectively. BAC: bacterial artificial chromosome vector backbone, 
YAC: yeast artificial chromosome vector backbone.
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be an effective adjuvant for the induction of a protective 
T
H1
-mediated cellular immune response to leishmaniasis. 
Intravenous vaccination of mice with engineered BCG cells 
led to a marked decrease of the diameter or the rate of pro-
gression of dermal lesions caused by a Leishmania mexicana 
challenge, although the extent of the response was dependent 
on the murine strain. 
The use of virulent bacteriophages to lyse pathogenic 
bacteria has a century-long history (Pennazio 2006). In the 
western world, the major application of this technology 
today is limited to the food industry and veterinary sciences 
(Atterbury 2009). Applying this process for humans in vivo, 
known as phage therapy, has had multiple eras of renaissance, 
but is today almost exclusively confined to countries formerly 
belonging to the USSR. However, a second generation of 
phage therapies seems to be emerging lately, which could 
provide yet another chance for this approach to gain ground 
in the west. This novel strategy applies genetically-engineered 
bacteriophages, and regards phages as mere delivery vehicles 
capable of inserting genetic constructs into bacteria for the 
purpose of their reprogramming. In a simple example, (Lu 
and Collins 2007) the T7 phage was engineered to express 
the dspB gene upon infection of the target cells. dspB encodes 
the dispersin enzyme, which is capable of degrading β-1,6-N-
acetyl D-glucosamine, the major extracellular polysaccharide 
component of biofilms formed by E. coli. Despite the fact 
that phages can only access bacteria residing at the surface 
of the biofilm, lysis of the infected cells will release dispersin 
to initiate the degradation of the polysaccharide matrix (Fig. 
8). This allows the released phage to re-infect deeper-lying 
cells of the biofilm, and ultimately to eradicate the targeted 
bacteria. In an in vitro test, the refactored phages were shown 
to decrease cell counts by 4.5 orders of magnitude, which 
meant a 100-fold increase in efficiency compared to the wild 
type phage.
In a more complex example, a non-lytic filamentous 
phage was used to influence a bacterial genetic circuit that 
is not targeted by current antibiotics (Lu and Collins 2009). 
This circuit was the SOS system, which can decrease cellular 
sensitivity to certain antibiotics by activating DNA-repair 
mechanisms in response to antibiotic-induced DNA-damage. 
In a proof-of concept experiment, phage infection generated 
lysogenic prophages expressing the lexA3 allele inside the 
targeted cells, which is an uninducible and dominant mutant 
repressor of the SOS circuit (Fig. 9). As a result, the number 
of cells surviving ofloxacin treatment was reduced nearly 
Figure 7. Cloning and engineering bacterial genomes in yeast (Lartigue et al. 2009). After the engineering is complete, the genomes are puri-
fied and transplanted into wild type bacterial cells.
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10,000-fold in vitro. In an in vivo experiment, the survival 
rate of mice intraperitoneally injected with E. coli was el-
evated from 20% to 90% when the ofloxacin treatment was 
complemented with the engineered bacteriophage. In the 
same publication, the workgroup demonstrated the possibility 
of increasing antibiotic-susceptibility via three further mecha-
nisms: i) expressing a porin (OmpF) that allows the uptake of 
an antibiotic; ii) overexpressing the repressor (SoxR) of an 
operon encoding anti-oxidative enzymes; and iii) expressing 
a master regulator (CsrA) to repress biofilm formation. In all 
examples, the phage treatment significantly facilitated the 
antibiotic effect in vitro, indicating the general applicability 
of this strategy.
The utility of phages as delivery vehicles has also been 
exploited in the development of “smart antibiotics”. These 
are CRISPR/Cas systems that target bacterial genes which 
pose a danger to the infected organism, e.g., antibiotic resis-
tance or virulence genes. In one of the first applications, an 
RNA-guided nuclease specific for the kanamycin-resistance 
gene was introduced into S. aureus cells using a phagemid 
Figure 8. Biofilm dispersal using engineered bacteriophages (Lu and Collins 2007). Dispersin, the product of the phage-encoded dspB gene is 
responsible for degrading the extracellular polysaccharide matrix of the biofilm and providing access to deeper lying cells in repeated cycles 
of infection and lysis.
Figure 9. Increasing sensitivity to antibiotics via repression of the SOS response (Lu and Collins 2009). The product of the lexA3 gene inserted 
into the bacterial cell by the transducing phage dominantly represses the SOS regulon, thereby avoiding the repair of the DNA damage caused 
by certain antibiotics.
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(Bikard et al. 2014). If the cells carried the resistance gene 
on the chromosome, their numbers could be reduced by up 
to 4 orders of magnitude due to the lethal effect of chromo-
somal cleavage. When the resistance gene was on a plasmid, 
99.99% of the population became sensitive to the antibiotic 
upon phagemid treatment, without substantial changes in the 
cell number. In addition, the retained phagemid provided the 
host bacteria immunity to re-transformation with the resis-
tance plasmid. In a parallel publication, conjugative plasmids 
were also demonstrated to be effective vectors for delivering 
RNA-guided nucleases into target cells (Citorik et al. 2014). 
In the same article, the survival curve of Galleria mellonella 
larvae infected with enterohaemorrhagic E. coli was shown 
to be significantly improved upon treatment with phagemids 
targeting a key virulence gene of the bacterium. Overall, both 
workgroups demonstrated the possibility of delicately restruc-
turing mixed microbial populations, and nearly completely 
eliminating lines that carry potentially hazardous genes. Since 
there is no massive elimination of commensals, the remain-
ing small fraction of targeted cells cannot go through a rapid 
expansion, as it often happens after incomplete antibiotic 
treatment. This warrants an extra level of safety for the future 
therapeutic use of RNA-guided nucleases. 
Although this review is not intended to deal with the 
engineering of eukaryotic cells, the in vivo cleavage of pro-
viral DNA using CRISPR/Cas should not be dismissed, for 
it stands on the borderline between targeted elimination of 
microbial parasites and gene therapy. The first such applica-
tion was that of Ebina et al. (2013), who targeted the LTR 
region of the human immunodeficiency virus (HIV) provirus, 
which plays a central role in the regulation of proviral gene 
expression. Using GFP-encoding proviral DNA integrated 
into immortalized human cell lines, they demonstrated that 
RNA-guided cleavage of he LTRs disrupted the HIV-1 ex-
pression machinery, suppressed proviral re-activation and 
promoted proviral excision. A similar strategy was used to 
destruct intrahepatic persistent hepatitis B virus (HBV) in a 
mouse model (Lin et al. 2014). The CRISPR/Cas encoding 
plasmid was introduced into mouse hepatocytes in vivo us-
ing hydrodynamics-based transfection (Suda and Liu 2007), 
which led to the significant decrease of the serum levels of the 
viral surface antigen. Cleavage of the oncogenes of the human 
papilloma virus (HPV) provirus in vivo may also be a promis-
ing approach to inhibit tumorigenesis, as demonstrated in a 
mouse model (Zhen et al. 2014). An HPV-16 positive human 
cervical cancer cell line was transfected with the CRISPR/
Cas plasmid targeting the E6 and E7 HPV oncogenes, as well 
as their promoter. The treated cells displayed reduced growth 
when transplanted into nude mice. 
Modified bacterial cells may provide future possibilities to 
inhibit viral infection in the first place. In a proof-of-principle 
study, Chang et al. (2003) engineered a natural vaginal isolate 
of Lactobacillus jensenii to secrete a soluble form of CD4, 
the primary cell surface receptor responsible for HIV-docking 
and entry (Fig. 10). A significant inhibition of viral infectiv-
ity in vitro was attainable with a simple co-incubation of the 
engineered bacteria with the viral particles. This demonstrates 
that reinforcing the human microflora with engineered strains 
could prove to be a promising strategy for successful control 
of infections. In a similar study, the E. coli Nissle strain was 
engineered to secrete an inhibitor peptide of gp41, the HIV-
protein responsible for membrane fusion and entry into target 
cells (Rao et al. 2005). 
Engineered bacteria can also be used to prevent diseases 
Figure 10. Inhibition of HIV binding by engineered Lactobacilli (Chang et al. 2003). The soluble CD4 molecules produced by modified Lactobacil-
lus jensenii inhibit the docking of HIV with CD4 receptors residing in the membrane of target cells.
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by influencing pathogenic bacterial strains through intercel-
lular signaling. For example, the growth and toxin-production 
of Vibrio cholerae is inhibited by the cholera autoinducer-1 
(CAI-1) molecule produced by V. cholerae at high cell densi-
ties. An engineered E. coli strain that produces CAI-1 could 
therefore serve as a protective agent against gastrointestinal 
cholera infection. Indeed, pre-treating mice with a CAI-1 
producer E. coli Nissle strain was shown to reduce intestinal 
cholera toxin quantities and V. cholerae cell counts by 80 
and 69%, respectively, and improve host survival by up to 
92% (Duan and March 2010). The application of refactored 
probiotic strains interfering with paracrine signaling therefore 
seems to be a useful strategy, and is by no means limited 
to treating or preventing infections. A summary of other 
engineered commensal strains secreting various factors to 
modulate human diseases is shown in Table 1. 
One can apply bacteria to affect human cells not only 
through secreted biomolecules, but also by direct contact and 
entry. The anti-cancer effect of certain obligate or facultative 
anaerobic bacteria is long known, for such cells display a 
tendency to grow and become enriched in the poor oxygen 
conditions typical of malignant tumors (for a review, see Hoff-
man 2012). The development of precise genome engineering 
methods and their application in bacteria nevertheless opened 
brand new possibilities in this field of research as well. In a 
ground-breaking experiment, the inv gene of Yersinia tuber-
culosis, encoding invasin was shown to be sufficient to con-
vert transformed E. coli into a microorganism able to invade 
Figure 11. Trans-kingdom RNA interference (Xiang et al. 2006). E. coli cells engineered to be invasive secrete short-hairpin RNAs (shRNA) with 
the help of lysteriolysin O to knock down the target CTNNB1 gene encoding β-catenin.
Strain Modification Effect Reference
Lactococcus lactis trefoil factors wound healing, cytoprotection Vandenbroucke et al. 2004, Caluwaerts et al. 2010
Lactococcus lactis LcrV anti-inflammation Foligne et al. 2007
Lactococcus lactis IL-10 anti-inflammation Schotte et al. 2000, Steidler et al. 2000
Lactococcus lactis HO-1 anti-inflammation Pang et al. 2008, Pang et al. 2009
Lactococcus lactis TNF-α nanobodies anti-inflammation Vandenbroucke et al. 2010
E. coli Nissle 1917 hEGFR wound healing Choi et al. 2012
Table 1. Examples of engineered probiotic bacterial strains.
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cultured mammalian cells (Isberg et al. 1987). Controlling inv 
expression by the hypoxia-regulated fdhF promoter allows 
the construction of bacteria acquiring the invasive phenotype 
only in hypoxic conditions, thereby limiting their intracellular 
action to the cores of tumors (Anderson et al. 2006). Express-
ing the lysteriolysin O of Lysteria monocytogenes in such 
engulfed cells allows the release of their cellular components 
for transfer to the invaded host (Grillot-Courvalin et al. 1998). 
In a proof-of-concept study, E. coli cells expressing invasin 
and lysteriolysin O were used to transmit shRNA targeting 
β-catenin into the invaded cells (Fig. 11). Intravenous treat-
ment of a mouse model of colon cancer with the engineered 
E. coli cells led to the significant decrease of the mRNA and 
protein levels of β-catenin within the tumor (Xiang et al. 
2006). Although the therapeutic effect of modified E. coli 
in cancer therapy is yet to be seen, such experiments readily 
highlight the possibility and potential of using trans-kingdom 
RNA interference for reprogramming tumor cells.
Conclusive remarks
In the sections above, we tried to give a complete picture on 
the toolbox available to engineer the genomes of microbial 
strains. The examples highlighted, however are by no means 
concise, and represent only the tip of the iceberg concerning 
the application of engineered bacteria and phages for improv-
ing human health. By illuminating the available techniques 
and the key strategies followed, our primary aim was to raise 
the interest of the reader, and provide the basics necessary to 
initiate the next project in this rapidly extending field.   
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